Efficacy

Aliqopa (Copanlisib) Efficacy in Treating Lymphoma

Aliqopa (copanlisib) is a kinase inhibitor specifically designed for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. The efficacy of Aliqopa in treating this type of lymphoma was demonstrated in a single-arm clinical trial. The main measure of efficacy was the overall response rate (ORR), which reflects the percentage of patients who achieved a partial or complete response to the treatment. In the trial, Aliqopa showed an ORR of 59%, with a complete response rate of 14% and a partial response rate of 45%. These results suggest that Aliqopa is effective in inducing a response in a significant proportion of patients with relapsed FL.

It is important to note that the duration of response (DOR) is also a critical aspect when evaluating the efficacy of lymphoma treatments. In the case of Aliqopa, the median DOR was 12.2 months, indicating that the responses achieved can be durable for a year or more in many patients. This duration is particularly meaningful for patients with relapsed disease, as treatment options may become more limited with each relapse.

Epkinly (Epcoritamab-bysp) Efficacy in Treating Lymphoma

Epkinly (epcoritamab-bysp) is an investigational bispecific antibody designed for the treatment of various types of B-cell non-Hodgkin lymphoma (NHL). As of the knowledge cutoff date, Epkinly is being evaluated in clinical trials and has not yet received regulatory approval. The efficacy of Epkinly is being assessed in terms of ORR, DOR, and progression-free survival (PFS) among other measures. Preliminary data from clinical trials have shown promising results, with Epkinly demonstrating an ability to induce responses in patients with relapsed or refractory NHL.

Specifically, in a phase 1/2 clinical trial, Epkinly has been reported to achieve an ORR in the range of 40-60% in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which is the most common subtype of NHL. The responses observed with Epkinly have included both complete and partial responses, suggesting that this therapy has the potential to be an effective treatment option for patients with DLBCL. Moreover, the DOR and PFS data, while still maturing, are anticipated to provide further insights into the long-term benefits of Epkinly in lymphoma treatment.